Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory Fiduciary Investigation

Berger Montague Investigates ADMA Biologics Board

Analysis based on 6 articles · First reported Aug 17, 2026 · Last updated Sep 08, 2026

Sentiment
-20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investigation raises concerns about ADMA Biologics' revenue recognition practices, potentially leading to a decline in investor confidence and stock price. Legal and regulatory scrutiny could result in financial penalties, restatements, or increased litigation costs for the company.

Biopharmaceuticals Legal Services

Berger Montague, a national plaintiffs' law firm, announced an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, a biopharmaceutical company. The investigation focuses on whether ADMA engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV, an intravenous immune globulin therapy for Primary Humoral Immunodeficiency. The firm is contacting shareholders to gather information and potentially pursue legal action. This investigation was announced via press releases on August 17, August 31, and September 8, 2026, indicating ongoing scrutiny. The allegations, if proven, could have significant implications for ADMA's financial reporting and shareholder trust.

80 Berger Montague announced investigation ADMA Biologics
stock
ADMA Biologics is the subject of the investigation; allegations of channel-stuffing could damage its reputation, lead to regulatory action, and negatively affect its stock price.
Importance 100.0 Sentiment -40.0
priv
Berger Montague is the law firm conducting the investigation, positioning itself to represent shareholders and potentially file a class action lawsuit against ADMA Biologics.
Importance 80.0 Sentiment 0.0
per
Andrew Abramowitz is a partner at Berger Montague involved in the investigation, serving as a contact for shareholders.
Importance 20.0 Sentiment 0.0
per
Caitlin Adorni is a professional at Berger Montague involved in the investigation, serving as a contact for shareholders.
Importance 20.0 Sentiment 0.0
Andrew Abramowitz co-counsel ↔ Caitlin Adorni Andrew Abramowitz is a professional colleague of Caitlin Adorni at Berger Montague, where they collaborate as co-counsel
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.